Reform FDA advisory committees and put rare disease patients first

Published Updated



The Food and Drug Administration (FDA) is failing patients with life-threatening rare diseases.

As a biochemist and public health expert, I have witnessed officials turning a blind eye to the needs, concerns, and voices of families caring for the nearly 30 million Americans — half of them children — with debilitating and terminal rare conditions.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.